United States Grants Additional Patent to Sequana Medical’s Revolutionary DSR® System

Sequana Medical NV (Euronext Brussels: SEQUA) proudly announces the granting of a new US patent for its revolutionary DSR (Direct Sodium Removal) program. This groundbreaking technology represents a major step forward in the treatment of fluid overload in liver disease, heart failure and cancer. With this new patent, Sequana Medical is continuing to cement its position as a pioneer in the field of medical treatments.

Sequana Medical has achieved a major milestone in its DSR therapy program with the granting of US patent 11,559,618 B2 on 24 January 2023. This patent covers an expanded composition of matter and methods, including additional oncotic and osmotic agents. With this addition, Sequana Medical now has 14 patents filed, 5 of which have been granted, offering a comprehensive range of coverage for its DSR program.

Sequana Medical’s Chief Executive Officer, Ian Crosbie, is pleased to announce the granting of an important patent for the company’s DSR program. This strengthens the IP protection for the program, which has already shown promising results in the SAHARA study. The next step is to file an IND for the second-generation DSR product and start the US Phase 1/2a randomized controlled study, MOJAVE, in patients with congestive heart failure. This is a huge step forward for the company, and could potentially revolutionize the treatment of heart failure.

About Sequana Medical

Sequana Medical NV is leading the way in treating fluid overload, a potentially fatal medical condition that affects patients with liver disease, heart failure and cancer. Up to 15 liters of extra fluid can accumulate in the bodies of these patients, causing severe pain, impaired breathing and restricted mobility – not to mention a significant reduction in quality of life. Standard diuretics are often ineffective or intolerable, leaving patients with limited options that can result in poor clinical outcomes, expensive treatments, and even death. Sequana Medical is dedicated to providing innovative solutions for this large, growing population of “diuretic-resistant” patients.

Sequana Medical has developed two proprietary platforms, alfapump® and DSR®, to treat diuretic-resistant fluid overload, providing major clinical and quality of life benefits for patients and reducing costs for healthcare systems. The positive primary endpoint data from the North American pivotal POSEIDON study of the alfapump in recurrent or refractory ascites due to liver cirrhosis has enabled the filing of a Pre-Market Approval (PMA) application with the FDA, planned for H2 2023. Furthermore, the successful clinical proof-of-concept for DSR as a disease-modifying drug program for the treatment of heart failure has paved the way for the upcoming MOJAVE, a US multi-centered randomized controlled Phase 1/2a clinical study of DSR 2.0, to commence in Q2 2023.

Leave a Comment